Cargando…
Advances in immune checkpoint inhibitors for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common cancer, and the second leading cause of cancer-related death worldwide. Although recent advances in immune checkpoint inhibitor-based immunotherapy have initiated a new era for advanced HCC treatment, the majority of HCC patients receiving immu...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Liver Cancer Association
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035682/ https://www.ncbi.nlm.nih.gov/pubmed/37383085 http://dx.doi.org/10.17998/jlc.2021.09.24 |